Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents

Disclosed is the use of a monoclonal antibody that specifically binds a TRAIL receptor DR5, wherein said antibody, in its soluble form, has in vivo and in vitro apoptosis-inducing activity in target cells expressing DR5, for preparation of a medicament for selectively inducing apoptosis in said targ...

Full description

Saved in:
Bibliographic Details
Main Authors KIMBERLEY, ROBERT P, ICHIKAWA, KIMIHISA, ZHOU, TONG, OSHUMI, JUN, LOBUGLIO, ALBERT F, KOOPMAN, WILLIAM J, BUCHSBAUM, DONALD J
Format Patent
LanguageEnglish
Published 28.08.2009
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Disclosed is the use of a monoclonal antibody that specifically binds a TRAIL receptor DR5, wherein said antibody, in its soluble form, has in vivo and in vitro apoptosis-inducing activity in target cells expressing DR5, for preparation of a medicament for selectively inducing apoptosis in said target cells, wherein said medicament is formulated for administration along with one or more therapeutic agents, wherein if the therapeutic agent is a chemotherapeutic agent, the chemotherapeutic agent is selected from the group consisting of leflunomide, dactinomycin, tamoxifen, interferon alpha-2b, glutamic acid, plicamycin, mercaptopurine, 6-thioguanine, carmustine, BCNU, lomustine, CCNU, cytosine, araboside, estramustine, hydroxyurea, procarbazine, bulsulfan, medroxyprogesterone, estramustine phosphate sodium, ethinyl estradiol, estradiol, megestrol acetate, methylestosteraone, diethylstilbestrol diphosphate, chlorotrianisene, testolactone, mephalen, chorambucil, mechlorethamine, thiotepa, bethamethasone sodium phosphate, dicarbazine, asparaginase, mitotane, vincristine sulphate and vinblastine sulphate. (62) (62) Divided Out of 533164
Bibliography:Application Number: NZ20020568727